| Joshua A Small, MD | |
|
2014 Washington St, Newton, MA 02462-1607 | |
| (617) 243-6040 | |
| Not Available |
| Full Name | Joshua A Small |
|---|---|
| Gender | Male |
| Speciality | Emergency Medicine |
| Experience | 21 Years |
| Location | 2014 Washington St, Newton, Massachusetts |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1922158963 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | 230746 (Massachusetts) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Newton-wellesley Hospital | Newton, MA | Hospital |
| South Shore Hospital | South weymouth, MA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| South Shore Health Express Inc | 6406108836 | 33 |
| Coastal Medical Associates | 7113029257 | 412 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
| Entity Name | Newton Wellesley Emergency Medicine Specialist Pc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1346355526 PECOS PAC ID: 7810983996 Enrollment ID: O20040423000237 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
| Entity Name | Coastal Medical Associates |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1932175684 PECOS PAC ID: 7113029257 Enrollment ID: O20070221000057 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
| Entity Name | Steward Emergency Physicians Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780971275 PECOS PAC ID: 0244401404 Enrollment ID: O20110919000768 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
| Entity Name | South Shore Health Express Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1477044212 PECOS PAC ID: 6406108836 Enrollment ID: O20181115000152 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
| Entity Name | Mass General Brigham Medical Group, Inc. |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1083360200 PECOS PAC ID: 3971987108 Enrollment ID: O20230925000368 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Joshua A Small, MD 27 Richard Rd, Needham, MA 02492-4321 Ph: (734) 255-0419 | Joshua A Small, MD 2014 Washington St, Newton, MA 02462-1607 Ph: (617) 243-6040 |
News Archive
Using a hand-held spectral domain optical coherence tomography (SD-OCT) imaging device, researchers have obtained high-resolution retinal scans of premature infants with progressive retinopathy of prematurity (ROP), according to a report in this month's Archives of Ophthalmology.
Oxygen Biotherapeutics, Inc. reported today that the Data Safety Monitoring Board overseeing the company's ongoing Phase II-b trial has, based on the results of the first cohort of patients, authorized the company to move forward with the next cohort of the study. This trial is a randomized, single-dose, placebo-controlled, double-blind, dose-escalation study to evaluate the safety and tolerability of our Oxycyte® emulsion in patients with severe non-penetrating traumatic brain injury.
BioCancell Therapeutics Inc. today announced that, pursuant to an effective registration statement on Form S-1 filed with the Securities and Exchange Commission, it intends to hold an auction in Israel on Thursday, November 18, 2010, for the sale of up to 617,000 units consisting, in the aggregate, of up to 6,170,000 shares of common stock, par value $0.01 per share, 3,085,000 Series 3 warrants and 3,085,000 Series 4 warrants.
COVID SHIELD is a major collaborative effort led by the Walter and Eliza Hall Institute of Medical Research in partnership with human data science company IQVIA.
› Verified 3 days ago
Dr. Jill Zimmer Simon, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6040 Fax: 617-243-6924 | |
Mary Christine Bailey, MD Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: 2014 Washington Street, Newton, MA 02462 Phone: 617-243-6040 Fax: 617-243-6924 | |
David Hark, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6192 | |
Andrew Woods Ames, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6040 Fax: 617-243-6924 | |
Lynanne Ballelli Morganstern, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: Mckesson Corporation, 275 Grove Street, Suite 1 - 110, Newton, MA 02466 Phone: 617-273-2966 | |
Barry J Tils, M.D. Emergency Medicine Medicare: Not Enrolled in Medicare Practice Location: Newton Wellesly Hospital, 2014 Washington Street, Newton, MA 02462 Phone: 617-243-6040 | |
Dr. David Storr Huckins, M.D. Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 2014 Washington St, Newton, MA 02462 Phone: 617-243-6193 |